AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== Food distribution in Latin America === Food distribution in Latin America is mainly dominated by large distributors and chains. Efforts have been made to compete with the industrialization of the food distribution system through the establishment of four types of organizations: consumer purchasing organizations, consumer cooperatives, voluntary chains, and retailer purchasing associations. Consumer purchasing organizations are groups of families who buy food together. The benefits of joining one of these organizations are the reduced cost and improved variety in diet that comes from purchasing food with other families. Consumer cooperatives differ from consumer purchasing organizations in that they are constituted by groups of individuals who work together to secure high quality food for low prices. The cooperatives are analogous to a food union that actively works to secure the rights of its consumers. Voluntary chains are organizations of privately owned retailers and food wholesalers who operate as one economic body. These groups form contracts to work under, but are economically independent of one another. Retailer purchasing organizations are groups of retailers who purchase products as though they were a single buyer. Members within these organizations are all involved in the purchasing of goods, but do not form contracts.
Once again, the German armies have invaded by force the territory of a neutral country, abusing its military potential. (...) For those who still think that neutrality is a guarantee of peace and salvation, the case of these two nations, small for their territory, but great for their sense of dignity and for their generous love of independence and sovereignty, should serve as an example and also as an encouragement. In April 1941, Avila Camacho ordered the seizure of German and Italian ships in national ports; among the ships thus seized was the Italian-flagged tanker Lucifero, which would later be called Potrero del Llano. It became evident that the government of Avila Camacho maintained a "simulated neutrality"; Mexico's material support was clearly for the Allied side. Two months later, another decree was published prohibiting the export of Mexican products to countries outside the American continent. This decision primarily affected Mexican oil, whose only major buyer would then be the United States, a country with which political tension was beginning to dissipate as the U.S. arms industry now required Mexico's raw material. On December 7, 1941, the Imperial Japanese Navy attacked Pearl Harbor, precipitating the Americans to abandon neutrality and enter the war which, from being purely European, thus became world-wide. Mexico, respecting the agreement of the Havana Conference of 1940, broke off relations with Japan and suspended all commercial exchanges with the Axis countries.
Lisa Feldman Barrett is a Canadian-American psychologist. She is a Distinguished Professor of psychology at Northeastern University, where she focuses on affective science and co-directs the Interdisciplinary Affective Science Laboratory. She has received the William James Fellow Award from the Association for Psychological Science for 2025, and the Award for Distinguished Scientific Contributions from the American Psychological Association for 2021, as well as a Guggenheim Fellowship. Along with James Russell, she is the founding editor-in-chief of the journal Emotion Review. Along with James Gross, she founded the Society for Affective Science.
==== Synthesis in Yoctoreactor ==== The yoctoreactor method introduced by Hansen et al. is based on the geometry and stability of a three-dimensional DNA structure that creates a yoctoliter (10−24 L) size chemical reactor in which proximity of BBs brings about reactions among them. The DNA oligomers comprise the DNA-barcode for the attached BBs and form the structural elements of the reactor. One kind of yoctoreactor format is shown in the figure.
Sources: en.wikipedia.org
Life-threatening overdose of opium tincture owes to the preparation's morphine content. Morphine produces a dose-dependent depressive effect on the respiratory system, which can lead to profound respiratory depression, hypoxia, coma and finally respiratory arrest and death. If overdose of opium tincture is suspected, rapid professional intervention is required. The primary concern is re-establishing a viable airway and institution of assisted or controlled ventilation if the patient is unable to breathe on their own. Other supportive measures such as the use of vasopressors and oxygen may be indicated to treat cardiac and/or pulmonary failure. Cardiac arrhythmias or arrest will require advanced life-saving measures. Intravenous naloxone or nalmefene, quick-acting opioid antagonists, are the first-line treatment to reverse respiratory depression caused by an overdose of opium tincture. Gastric lavage may be of some use in certain cases.
According to the 2022 Brazilian census, 45.3% of the population (92.1 million) described themselves as Pardo (meaning brown or multiracial), 43.5% (88.2 million) as White, 10.2% (20.7 million) as Black, 0.6% (1.2 million) as Indigenous and 0.4% (850,000) as East Asian (officially called yellow or amarela). Since the arrival of the Portuguese in 1500, considerable genetic mixing between Amerindians, Europeans, and Africans has taken place in all regions of the country:
Many foods are rich in the amino acids and nucleotides imparting umami. Naturally occurring glutamate can be found in meats and vegetables. Inosine (IMP) comes primarily from meats and guanosine (GMP) from vegetables. Mushrooms, especially dried shiitake, are rich sources of umami flavor from guanylate. Smoked or fermented fish are high in inosinate, and shellfish in adenylate. Protein in food is tasteless, however processes such as fermentation, curing, or heat treatment release glutamate and other amino acids. Generally, umami taste is common to foods that contain high levels of L-glutamate, IMP and GMP, most notably in fish, shellfish, cured meats, meat extracts, mushrooms, vegetables (e.g., ripe tomatoes, Chinese cabbage, spinach, celery, etc.), green tea, hydrolyzed vegetable protein, and fermented and aged products involving bacterial or yeast cultures, such as cheeses, shrimp pastes, fish sauce, soy sauce, natto, nutritional yeast, and yeast extracts such as Vegemite and Marmite. Studies have shown that the amino acids in breast milk are often the first encounter humans have with umami. Glutamic acid makes up half of the free amino acids in breast milk.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.